Enhancement of eCB-MSC Cryorecovery

Our research project aims to preserve the post-thaw viability and functionality of mesenchymal stem cells (MSCs) derived from equine cord blood (eCB-MSCs). The project addresses the challenge posed by asynchronous culture paired with dimethyl sulfoxide (DMSO)-based cryopreservation, which may lead to cryoinjury, batch variability, and reduced therapeutic effectiveness. By investigating a novel DMSO-free cryoprotective agent in combination with cell-cycle synchronization via serum starvation, the research seeks to establish a more reliable cryopreservation protocol that better preserves the cells’ regenerative potential.

eQcell Inc. focuses on veterinary regenerative solutions while generating pre-clinical data to establish scientifically and economically efficient pathways for translating these advancements to human applications, utilizing a One Health approach. Through this research, eQcell aims to overcome the limitations of existing cryopreservation methods by improving the consistency, viability, and functionality of eCB-MSCs post-thaw. The successful development of a DMSO-free cryopreservation protocol could significantly enhance the therapeutic outcomes of MSC treatments, positioning eQcell at the forefront of equine regenerative medicine and potentially opening up new economic opportunities in the biotechnology sector.

Faculty Supervisor:

Sarah Lepage

Student:

Partner:

eQcell

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Guelph

Program: